Literature DB >> 31498388

Cancer Risk in Inflammatory Bowel Disease: A 6-Year Prospective Multicenter Nested Case-Control IG-IBD Study.

Livia Biancone1, Alessandro Armuzzi2, Maria Lia Scribano3, Fabiana Castiglione4, Renata D'Incà5, Ambrogio Orlando6, Claudio Papi7, Marco Daperno8, Maurizio Vecchi9, Gabriele Riegler10, Walter Fries11, Patrizia Alvisi12, Gianmichele Meucci13, Filippo Mocciaro14, Francesca Rogai15, Stefano Festa7, Luisa Guidi2, Anna Testa4, Luisa Spina16, Sara Renna6, Anna Viola11, Marta Patturelli10, Roberto Di Mitri14, Iris Frankovic5, Emma Calabrese1, Carmelina Petruzziello1, Elena De Cristofaro1, Giorgia Sena1, Alessandra Ruffa1, Benedetto Neri1, Alessandra Rossi1.   

Abstract

BACKGROUND: In a 6-year, multicenter, prospective nested case-control study, we aimed to evaluate risk factors for incident cancer in inflammatory bowel disease (IBD), when considering clinical characteristics of IBD and immunomodulator use. The secondary end point was to provide characterization of incident cancer types.
METHODS: All incident cases of cancer occurring in IBD patients from December 2011-2017 were prospectively recorded in 16 Italian Group for the Study of Inflammatory Bowel Disease units. Each of the IBD patients with a new diagnosis of cancer was matched with 2 IBD patients without cancer, according to IBD phenotype (ulcerative colitis [UC] vs Crohn's disease [CD]), age (±5 years), sex. Risk factors were assessed by multivariate logistic regression analysis.
RESULTS: Cancer occurred in 403 IBD patients: 204 CD (CD cases), 199 UC (UC cases). The study population included 1209 patients (403 IBD cases, 806 IBD controls). Cancer (n = 403) more frequently involved the digestive system (DS; 32%), followed by skin (14.9%), urinary tract (9.7%), lung (6.9%), genital tract (6.5%), breast (5.5%), thyroid (1.9%), lymphoma (2.7%, only in CD), adenocarcinoma of the small bowel (SBA; 3.9%, 15 CD, 1 pouch in UC), other cancers (15.9%). Among cancers of the DS, colorectal cancer (CRC) more frequently occurred in UC (29% vs 17%; P < 0.005), whereas SBA more frequently occurred in CD (13% vs 6.3% P = 0.039). In CD, perforating (B3) vs non-stricturing non-perforating (B1) behavior represented the only risk factor for any cancer (odds ratio [OR], 2.33; 95% confidence interval [CI], 1.33-4.11). In CD, risk factors for extracolonic cancer (ECC) were a B3 vs B1 and a stricturing (B2) vs B1 behavior (OR, 2.95; 95% CI, 1.62-5.43; OR, 1.79; 95% CI, 1.09-2.98). In UC, risk factors for ECC and for overall cancer were abdominal surgery for UC (OR, 4.63; 95% CI, 2.62-8.42; OR, 3.34; 95% CI, 1.88-5.92) and extensive vs distal UC (OR, 1.73; 95% CI, 1.10-2.75; OR, 1.99; 95% CI, 1.16-3.47). Another risk factor for ECC was left-sided vs distal UC (OR, 1.68; 95% CI, 1.00-2.86). Inflammatory bowel disease duration was a risk factor for skin and urinary tract cancers.
CONCLUSIONS: Perforating CD, extensive UC, and abdominal surgery for UC were identified as risk factors for overall incident cancer and for ECC. The clinical characteristics associated with severe IBD may increase cancer risk.
© 2019 Crohn’s & Colitis Foundation. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  cancer risk; clinical characteristics; immunomodulators; inflammatory bowel disease; multicenter prospective nested case–control study

Year:  2020        PMID: 31498388     DOI: 10.1093/ibd/izz155

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  13 in total

Review 1.  Sex matters: impact on pathogenesis, presentation and treatment of inflammatory bowel disease.

Authors:  Wendy A Goodman; Ian P Erkkila; Theresa T Pizarro
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-09-08       Impact factor: 46.802

2.  miRNA-320 inhibits colitis-associated colorectal cancer by regulating the IL-6R/STAT3 pathway in mice.

Authors:  Meng-Yao Wu; Yu-Xin Luo; Wen-Xiu Jia; Dan-Dan Wang; Dong-Lei Sun; Jia Song; Jing Wang; Wei-Wei Niu; Xiao-Lan Zhang
Journal:  J Gastrointest Oncol       Date:  2022-04

3.  Small bowel adenocarcinoma in Crohn's disease: a systematic review and meta-analysis of the prevalence, manifestation, histopathology, and outcomes.

Authors:  Yip Han Chin; Sneha Rajiv Jain; Ming Hui Lee; Cheng Han Ng; Snow Yunni Lin; Aaron Shengting Mai; Mark Dhinesh Muthiah; Fung Joon Foo; Raghav Sundar; David Eng Hui Ong; Wei Qiang Leow; Rupert Leong; Webber Pak Wo Chan
Journal:  Int J Colorectal Dis       Date:  2021-10-26       Impact factor: 2.571

4.  Managing IBD in patients with previous cancers.

Authors:  Sarah E Minnis-Lyons; Zara Aiken; Shien Chow; Shahida Din
Journal:  Frontline Gastroenterol       Date:  2022-06-08

5.  Comparative Effectiveness of Surveillance Colonoscopy Intervals on Colorectal Cancer Outcomes in a National Cohort of Patients with Inflammatory Bowel Disease.

Authors:  Hyun-Seok Kim; Ruben Hernaez; Shubhada Sansgiry; Akbar K Waljee; Frank I Scott; James D Lewis; Hashem B El-Serag; Jason K Hou
Journal:  Clin Gastroenterol Hepatol       Date:  2022-02-28       Impact factor: 13.576

6.  Saffron Pre-Treatment Promotes Reduction in Tissue Inflammatory Profiles and Alters Microbiome Composition in Experimental Colitis Mice.

Authors:  Suhrid Banskota; Hassan Brim; Yun Han Kwon; Gulshan Singh; Sidhartha R Sinha; Huaqing Wang; Waliul I Khan; Hassan Ashktorab
Journal:  Molecules       Date:  2021-06-02       Impact factor: 4.411

7.  Ulcerative Colitis With Concomitant Serrated Polyposis Syndrome: A Case Report and Literature Review.

Authors:  Mahmoud M Mansour; Zachary D Smith; Yezaz Ghouri; Veysel Tahan
Journal:  Cureus       Date:  2021-04-20

Review 8.  Extracellular Matrix Mechanical Properties and Regulation of the Intestinal Stem Cells: When Mechanics Control Fate.

Authors:  Lauriane Onfroy-Roy; Dimitri Hamel; Julie Foncy; Laurent Malaquin; Audrey Ferrand
Journal:  Cells       Date:  2020-12-07       Impact factor: 6.600

Review 9.  The Regulation of Intestinal Inflammation and Cancer Development by Type 2 Immune Responses.

Authors:  Reyes Gamez-Belmonte; Lena Erkert; Stefan Wirtz; Christoph Becker
Journal:  Int J Mol Sci       Date:  2020-12-21       Impact factor: 5.923

Review 10.  Solid extraintestinal malignancies in patients with inflammatory bowel disease.

Authors:  Anastasia Mala; Kalliopi Foteinogiannopoulou; Ioannis E Koutroubakis
Journal:  World J Gastrointest Oncol       Date:  2021-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.